You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 49 No. 11, November 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Naltrexone in the Treatment of Alcohol Dependence

Joseph R. Volpicelli, MD, PhD; Arthur I. Alterman, PhD; Motoi Hayashida, MD, ScD; Charles P. O'Brien, MD, PhD

Arch Gen Psychiatry. 1992;49(11):876-880.


Abstract

• Seventy male alcohol-dependent patients participated in a 12-week, double-blind, placebo-controlled trial of naltrexone hydrochloride (50 mg/d) as an adjunct to treatment following alcohol detoxification. Subjects taking naltrexone reported significantly less alcohol craving and days in which any alcohol was consumed. During the 12-week study, only 23% of the naltrexone-treated subjects met the criteria for a relapse, whereas 54.3% of the placebo-treated subjects relapsed. The primary effect of naltrexone was seen in patients who drank any alcohol while attending outpatient treatment. Nineteen (95%) of the 20 placebo-treated patients relapsed after they sampled alcohol, while only eight (50%) of 16 naltrexone-treated patients exposed to alcohol met relapse criteria. Naltrexone was not associated with mood changes or other psychiatric symptoms. Significant side effects (nausea) occurred in two nalterxonetreated subjects, and one naltrexone-treated subject complained of increased pain from arthritis. These results suggest that naltrexone may be a safe and effective adjunct to treatment in alcohol-dependent subjects, particularly in preventing alcohol relapse.



Author Affiliations

From the Department of Psychiatry, University of Pennsylvania, Philadelphia, and the Philadelphia Veterans Affairs Medical Center.


Footnotes

Accepted for publication February 8, 1992.

Presented in part at a satellite symposium associated with the annual session of the meeting of the Society of Neuroscience, November 12, 1988, Toronto, Ontario.

Reprint requests to Treatment Research Center, 3900 Chestnut St, Philadelphia, PA 19104 (Dr Volpicelli).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Sweet Liking Phenotype, Alcohol Craving and Response to Naltrexone Treatment in Alcohol Dependence
Garbutt et al.
Alcohol Alcohol 2009;44:293-300.
ABSTRACT | FULL TEXT  

Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel
Physiol. Rev. 2009;89:649-705.
ABSTRACT | FULL TEXT  

Evidence-based treatments of addiction
O'Brien
Phil Trans R Soc B 2008;363:3277-3286.
ABSTRACT | FULL TEXT  

Effect of Naltrexone and Ondansetron on Alcohol Cue-Induced Activation of the Ventral Striatum in Alcohol-Dependent People
Myrick et al.
Arch Gen Psychiatry 2008;65:466-475.
ABSTRACT | FULL TEXT  

Prospects for a Genomic Approach to the Treatment of Alcoholism
O'Brien
Arch Gen Psychiatry 2008;65:132-133.
FULL TEXT  

Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes
Rosner et al.
J Psychopharmacol 2008;22:11-23.
ABSTRACT  

Longitudinal Course of Substance Treatment Benefits in Older Male Veteran At-Risk Drinkers
Zanjani et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2008;63:98-106.
ABSTRACT | FULL TEXT  

Effects of Naltrexone on Alcohol Sensitivity and Genetic Moderators of Medication Response: A Double-blind Placebo-Controlled Study
Ray and Hutchison
Arch Gen Psychiatry 2007;64:1069-1077.
ABSTRACT | FULL TEXT  

Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
Steensland et al.
Proc. Natl. Acad. Sci. USA 2007;104:12518-12523.
ABSTRACT | FULL TEXT  

Prevalence, Correlates, Disability, and Comorbidity of DSM-IV Alcohol Abuse and Dependence in the United States: Results From the National Epidemiologic Survey on Alcohol and Related Conditions
Hasin et al.
Arch Gen Psychiatry 2007;64:830-842.
ABSTRACT | FULL TEXT  

Association of a Functional Polymorphism in the {micro}-Opioid Receptor Gene With Alcohol Response and Consumption in Male Rhesus Macaques
Barr et al.
Arch Gen Psychiatry 2007;64:369-376.
ABSTRACT | FULL TEXT  

Emerging approaches to managing alcohol dependence
SWIFT
Am J Health Syst Pharm 2007;64:S12-S22.
ABSTRACT | FULL TEXT  

Presynaptic {delta} Opioid Receptors Regulate Ethanol Actions in Central Amygdala
Kang-Park et al.
J. Pharmacol. Exp. Ther. 2007;320:917-925.
ABSTRACT | FULL TEXT  

Guideline Watch (April 2007): Practice Guideline for the Treatment of Patients With Substance Use Disorders, 2nd Edition
Connery and Kleber
Focus 2007;5:163-166.
ABSTRACT | FULL TEXT  

Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram
Petrakis et al.
Schizophr Bull 2006;32:644-654.
ABSTRACT | FULL TEXT  

Nociceptin/orphanin FQ presynaptically decreases GABAergic transmission and blocks the ethanol-induced increase of GABA release in central amygdala
Roberto and Siggins
Proc. Natl. Acad. Sci. USA 2006;103:9715-9720.
ABSTRACT | FULL TEXT  

Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes
Wang et al.
J. Leukoc. Biol. 2006;79:1166-1172.
ABSTRACT | FULL TEXT  

COMBINED ACAMPROSATE AND NALTREXONE, WITH COGNITIVE BEHAVIOURAL THERAPY IS SUPERIOR TO EITHER MEDICATION ALONE FOR ALCOHOL ABSTINENCE: A SINGLE CENTRES' EXPERIENCE WITH PHARMACOTHERAPY
FEENEY et al.
Alcohol Alcohol 2006;41:321-327.
ABSTRACT | FULL TEXT  

Association between two {micro}-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence
Zhang et al.
Hum Mol Genet 2006;15:807-819.
ABSTRACT | FULL TEXT  

Multicenter Investigation of the Opioid Antagonist Nalmefene in the Treatment of Pathological Gambling
Grant et al.
Am. J. Psychiatry 2006;163:303-312.
ABSTRACT | FULL TEXT  

Naltrexone and problems in pain management
Vickers and Jolly
BMJ 2006;332:132-133.
FULL TEXT  

Pharmacokinetics of Long-Acting Naltrexone in Subjects With Mild to Moderate Hepatic Impairment
Turncliff et al.
J Clin Pharmacol 2005;45:1259-1267.
ABSTRACT | FULL TEXT  

Reduction of ethanol intake by chronic treatment with Hypericum perforatum, alone or combined with naltrexone in rats
Perfumi et al.
J Psychopharmacol 2005;19:448-454.
ABSTRACT  

Anticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O'Brien
Am. J. Psychiatry 2005;162:1423-1431.
ABSTRACT | FULL TEXT  

Review: naltrexone reduces alcohol consumption (in the short-term) in patients with alcohol dependence
Graham
Evid. Based Med. 2005;10:120-120.
FULL TEXT  

CLINICAL PREDICTORS OF RESPONSE TO NALTREXONE IN ALCOHOLIC PATIENTS: WHO BENEFITS MOST FROM TREATMENT WITH NALTREXONE?
RUBIO et al.
Alcohol Alcohol 2005;40:227-233.
ABSTRACT | FULL TEXT  

Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial
Garbutt et al.
JAMA 2005;293:1617-1625.
ABSTRACT | FULL TEXT  

INTERACTIONS BETWEEN CANNABINOID AND OPIOID RECEPTOR SYSTEMS IN THE MEDIATION OF ETHANOL EFFECTS
MANZANARES et al.
Alcohol Alcohol 2005;40:25-34.
ABSTRACT | FULL TEXT  

Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care: A Nested Sequence of 3 Randomized Trials
O'Malley et al.
Arch Intern Med 2003;163:1695-1704.
ABSTRACT | FULL TEXT  

Substance-Related Disorders
Mack and Frances
Focus 2003;1:125-146.
ABSTRACT | FULL TEXT  

Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial
Anton et al.
Focus 2003;1:183-189.
ABSTRACT | FULL TEXT  

Bridging the Gap: A Hybrid Model to Link Efficacy and Effectiveness Research in Substance Abuse Treatment
Carroll and Rounsaville
Psychiatr. Serv. 2003;54:333-339.
ABSTRACT | FULL TEXT  

COMPARISON OF CYANAMIDE AND PLACEBO IN THE TREATMENT OF ALCOHOL DEPENDENCE OF ADOLESCENTS
Niederhofer et al.
Alcohol Alcohol 2003;38:50-53.
ABSTRACT | FULL TEXT  

Comparing and Combining Naltrexone and Acamprosate in Relapse Prevention of Alcoholism: A Double-blind, Placebo-Controlled Study
Kiefer et al.
Arch Gen Psychiatry 2003;60:92-99.
ABSTRACT | FULL TEXT  

The Gap Between Research and Practice in Substance Abuse Treatment
Marinelli-Casey et al.
Psychiatr. Serv. 2002;53:984-987.
ABSTRACT | FULL TEXT  

The Effect of Chronic Ethanol Consumption and Withdrawal on {micro}-Opioid and Dopamine D1 and D2 Receptor Density in Fawn-Hooded Rat Brain
Djouma and Lawrence
J. Pharmacol. Exp. Ther. 2002;302:551-559.
ABSTRACT | FULL TEXT  

CONTRIBUTION OF FRONTAL CEREBRAL BLOOD FLOW MEASURED BY 99mTc-BICISATE SPECT AND EXECUTIVE FUNCTION DEFICITS TO PREDICTING TREATMENT OUTCOME IN ALCOHOL-DEPENDENT PATIENTS
Noel et al.
Alcohol Alcohol 2002;37:347-354.
ABSTRACT | FULL TEXT  

Behavioral Neurobiology of Alcohol Addiction: Recent Advances and Challenges
Weiss and Porrino
J. Neurosci. 2002;22:3332-3337.
ABSTRACT | FULL TEXT  

SHORT-TERM METHADONE ADMINISTRATION REDUCES ALCOHOL CONSUMPTION IN NON-ALCOHOLIC HEROIN ADDICTS
Caputo et al.
Alcohol Alcohol 2002;37:164-168.
ABSTRACT | FULL TEXT  

Naltrexone in the Treatment of Alcohol Dependence
Krystal et al.
NEJM 2001;345:1734-1739.
ABSTRACT | FULL TEXT  

Naltrexone Treatment for Alcohol Dependence
Fuller and Gordis
NEJM 2001;345:1770-1771.
FULL TEXT  

NALTREXONE, A RELAPSE PREVENTION MAINTENANCE TREATMENT OF ALCOHOL DEPENDENCE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Streeton and Whelan
Alcohol Alcohol 2001;36:544-552.
ABSTRACT | FULL TEXT  

NALTREXONE VERSUS ACAMPROSATE: ONE YEAR FOLLOW-UP OF ALCOHOL DEPENDENCE TREATMENT
Rubio et al.
Alcohol Alcohol 2001;36:419-425.
ABSTRACT | FULL TEXT  

Functional Interaction between Opioid and Cannabinoid Receptors in Drug Self-Administration
Navarro et al.
J. Neurosci. 2001;21:5344-5350.
ABSTRACT | FULL TEXT  

The Patient Recovering from Alcohol or Drug Addiction: Special Issues for the Anesthesiologist
May et al.
Anesth. Analg. 2001;92:1601-1608.
FULL TEXT  

Alcoholism Treatment After Liver Transplantation: Lessons Learned From a Clinical Trial That Failed
Weinrieb et al.
Psychosomatics 2001;42:110-116.
ABSTRACT | FULL TEXT  

Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence
Tomkins and Sellers
CMAJ 2001;164:817-821.
ABSTRACT | FULL TEXT  

Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism
Sinclair
Alcohol Alcohol 2001;36:2-10.
ABSTRACT | FULL TEXT  

Outpatient Management of Patients with Alcohol Problems
Fiellin et al.
ANN INTERN MED 2000;133:815-827.
ABSTRACT | FULL TEXT  

Sequence variability and candidate gene analysis in complex disease: association of {micro} opioid receptor gene variation with substance dependence
Hoehe et al.
Hum Mol Genet 2000;9:2895-2908.
ABSTRACT | FULL TEXT  

A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ABUSE
Chick et al.
Alcohol Alcohol 2000;35:587-593.
ABSTRACT | FULL TEXT  

Drug Dependence, a Chronic Medical Illness: Implications for Treatment, Insurance, and Outcomes Evaluation
McLellan et al.
JAMA 2000;284:1689-1695.
ABSTRACT | FULL TEXT  

THE LONG-TERM COST-EFFECTIVENESS OF IMPROVING ALCOHOL ABSTINENCE WITH ADJUVANT ACAMPROSATE
Palmer et al.
Alcohol Alcohol 2000;35:478-492.
ABSTRACT | FULL TEXT  

Naltrexone plus cognitive behavioural therapy led to fewer drinking relapses in outpatients with alcoholism
Chick
Evid. Based Ment. Health 2000;3:75-75.
FULL TEXT  

{micro}-Opioid Receptor Knockout Mice Do Not Self-Administer Alcohol
Roberts et al.
J. Pharmacol. Exp. Ther. 2000;293:1002-1008.
ABSTRACT | FULL TEXT  

Novel Uncompetitive N-Methyl-D-Aspartate (NMDA)-Receptor Antagonist MRZ 2/579 Suppresses Ethanol Intake in Long-Term Ethanol-Experienced Rats and Generalizes to Ethanol Cue in Drug Discrimination Procedure
Hölter et al.
J. Pharmacol. Exp. Ther. 2000;292:545-552.
ABSTRACT | FULL TEXT  

Oral nalmefene reduced relapse to heavy drinking and was well tolerated in patients with alcohol dependence
Chick
Evid. Based Ment. Health 2000;3:20-20.
FULL TEXT  

COMBINATION PHARMACOTHERAPY: A MIXTURE OF SMALL DOSES OF NALTREXONE, FLUOXETINE, AND A THYROTROPIN-RELEASING HORMONE ANALOGUE REDUCES ALCOHOL INTAKE IN THREE STRAINS OF ALCOHOL-PREFERRING RATS
Rezvani et al.
Alcohol Alcohol 2000;35:76-83.
ABSTRACT | FULL TEXT  

Naltrexone and Cognitive Behavioral Therapy for the Treatment of Outpatient Alcoholics: Results of a Placebo-Controlled Trial
Anton et al.
Am. J. Psychiatry 1999;156:1758-1764.
ABSTRACT | FULL TEXT  

Occurrence and Management of Depression in the Context of Naltrexone Treatment of Alcoholism
Farren and O'Malley
Am. J. Psychiatry 1999;156:1258-1262.
FULL TEXT  

A Double-blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence
Mason et al.
Arch Gen Psychiatry 1999;56:719-724.
ABSTRACT | FULL TEXT  

Opioids, Reward and Addiction: An Encounter of Biology, Psychology, and Medicine
van Ree et al.
Pharmacol. Rev. 1999;51:341-396.
ABSTRACT | FULL TEXT  

Drug Therapy for Alcohol Dependence
Swift
NEJM 1999;340:1482-1490.
FULL TEXT  

Role of the Primary Care Physician in Problems of Substance Abuse
Weaver et al.
Arch Intern Med 1999;159:913-924.
ABSTRACT | FULL TEXT  

PERSONALITY AND ALCOHOL/SUBSTANCE-USE DISORDER PATIENT RELAPSE AND ATTENDANCE AT SELF-HELP GROUP MEETINGS
Janowsky et al.
Alcohol Alcohol 1999;34:359-369.
ABSTRACT | FULL TEXT  

Pharmacological Treatment of Alcohol Dependence: A Review of the Evidence
Garbutt et al.
JAMA 1999;281:1318-1325.
ABSTRACT | FULL TEXT  

Adrenocorticotropin Responses to Naloxone in Sons of Alcohol-Dependent Men
Wand et al.
J. Clin. Endocrinol. Metab. 1999;84:64-68.
ABSTRACT | FULL TEXT  

Family History of Alcoholism and Hypothalamic Opioidergic Activity
Wand et al.
Arch Gen Psychiatry 1998;55:1114-1119.
ABSTRACT | FULL TEXT  

Contribution of the Opioid System to Alcohol Aversion and Alcohol Drinking Behavior
Froehlich et al.
J. Pharmacol. Exp. Ther. 1998;287:284-292.
ABSTRACT | FULL TEXT  

Patients with Alcohol Problems
O'Connor and Schottenfeld
NEJM 1998;338:592-602.
FULL TEXT  

Drug Development for Disorders of the Nervous System: Challenge and Opportunity at the Pharmaceutical-Biotech-Academic Interface
Schmidt
Neuroscientist 1998;4:9-13.
ABSTRACT  

The Safety Profile of Naltrexone in the Treatment of Alcoholism: Results From a Multicenter Usage Study
Croop et al.
Arch Gen Psychiatry 1997;54:1130-1135.
ABSTRACT  

{blacktriangledown}Acamprosate for alcohol dependence?
DTB 1997;35:70-72.
ABSTRACT | FULL TEXT  

Naltrexone and Alcohol Dependence: Role of Subject Compliance
Volpicelli et al.
Arch Gen Psychiatry 1997;54:737-742.
ABSTRACT  

Addiction Medicine
O'Brien and McLellan
JAMA 1997;277:1840-1841.
 

Science, medicine, and the future: Substance use disorders
Schuckit
BMJ 1997;314:1605-1605.
FULL TEXT  

Daidzin inhibits mitochondrial aldehyde dehydrogenase and suppresses ethanol intake of Syrian golden hamsters
Keung et al.
Proc. Natl. Acad. Sci. USA 1997;94:1675-1679.
ABSTRACT | FULL TEXT  

Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass et al.
Arch Gen Psychiatry 1996;53:673-680.
ABSTRACT  

Addiction Medicine
Wesson and Ling
JAMA 1996;275:1792-1793.
ABSTRACT  

Management of Cocaine Abuse and Dependence
Mendelson and Mello
NEJM 1996;334:965-972.
FULL TEXT  

A Double-blind, Placebo-Controlled Trial of Desipramine for Primary Alcohol Dependence Stratified on the Presence or Absence of Major Depression
Mason et al.
JAMA 1996;275:761-767.
ABSTRACT  

Alcohol Research: At the Cutting Edge
Gordis
Arch Gen Psychiatry 1996;53:199-201.
ABSTRACT  

Six-Month Follow-up of Naltrexone and Psychotherapy for Alcohol Dependence
O'Malley et al.
Arch Gen Psychiatry 1996;53:217-224.
ABSTRACT  

The Obsessive Compulsive Drinking Scale: A New Method of Assessing Outcome in Alcoholism Treatment Studies
Anton et al.
Arch Gen Psychiatry 1996;53:225-231.
ABSTRACT  

Imipramine Treatment of Alcoholics With Primary Depression: A Placebo-Controlled Clinical Trial
McGrath et al.
Arch Gen Psychiatry 1996;53:232-240.
ABSTRACT  

Enhanced Sensitivity of Pituitary {beta}Endorphin to Ethanol in Subjects at High Risk of Alcoholism
Gianoulakis et al.
Arch Gen Psychiatry 1996;53:250-257.
ABSTRACT  

A Man With Alcoholism and HIV Infection
Hyman
JAMA 1995;274:837-843.
ABSTRACT  

Addiction Medicine
Franklin
JAMA 1995;273:1656-1657.
ABSTRACT  

Naltrexone and Alcohol Dependence: Some Methodological Issues
Andrade and Kumar Rao
Arch Gen Psychiatry 1994;51:335-335.
ABSTRACT  

Naltrexone and Alcohol Dependence: Some Methodological Issues-Reply
Volpicelli et al.
Arch Gen Psychiatry 1994;51:335-336.
ABSTRACT  

Addiction Medicine
Franklin
JAMA 1993;270:184-185.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.